AI-powered tissue analysis, validated by pathologists.
PathoSearch makes tissue images easier to search, opening another route to finding patterns researchers might otherwise miss.
Drug discovery, biotechnology, diagnostics, medical devices and healthcare software. A Cosign selection of startups, scaleups and selected public or acquired companies, listed alphabetically.
Cosign
New gene-insertion results test whether models learning from nature’s diversity can produce tools for programming medicines.
Bristol Myers Squibb signed on in August, putting AI molecule design against a drugmaker’s real discovery problems.
Opening the World of Biology to New Possibilities
It’s moving from research sequencing toward diagnostic instruments. The next hurdle is bringing richer biological measurements into the workflows that guide patient care.
Community health intelligence from wastewater.
Wastewater tests across 1,000 locations look for population-wide health signals before individual cases tell the full story.
Its commercial T-cell tools tackle the manufacturing step that can keep advanced therapies difficult to produce.
Rehab robots are working in a center serving thousands of patients, bringing repeatable physical training into clinical care.
Genome engineering and reproductive research for conservation and species restoration.
Artificial-egg hatching research could make fragile reproduction easier to support, with implications for conserving threatened species.
Mapping three hundred cell states expands the possibilities for programming cells to restore functions disease takes away.
Noninvasive cardiac sensing and heart-pressure analysis for clinicians.
FDA authorization opens a route to estimating heart pressure without a catheter, making an important heart-failure measurement easier to access.
Five hospitals. 1.2 million people. Metro South is rolling Heidi out after 92% of trial clinicians reported less admin.
Bioprinted tissue therapies designed to restore biological function.
More Novo Nordisk technology and responsibility brings its goal of replacing lost biological function with living tissue closer.
Automated stem cell manufacturing for personalized regenerative medicine.
New tissue-manufacturing results tackle a hard limit on cell therapies: making the same living product reliably, again and again.
Anatomical imaging projected directly onto patients
A near-production prototype advances the idea of putting anatomy directly in a surgeon’s view, with clinical validation still ahead.
